---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-26-000007"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:04:43.604656+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics reports record $3.18B FY2025 revenue; EPS $27.86 diluted

## Summary
- FY 2025 revenue hit record $3.18B (+11% YoY); net income $1.33B ($27.86 diluted EPS) vs $1.20B ($24.64) in 2024.
- Q4 revenue $790.2M (+7%); net income $364.3M ($7.70 diluted EPS) vs $301.3M ($6.19).
- Tyvaso DPI sales $1.29B (+25% YoY); total Tyvaso $1.88B (+16%).
- Orenitram sales $496.9M (+14% YoY).
- Repurchased $1.0B of stock in 2025; litigation accrual reduced to $3M from $71.1M in 2024.

## SEC filing metadata
- accession: 0001082554-26-000007
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000007/0001082554-26-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255426000007/uthr-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-26-000007
- JSON: https://secwatch.observer/filing/0001082554-26-000007.json
- Plain text: https://secwatch.observer/filing/0001082554-26-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.